# **Proteome Sciences plc**

# ("Proteome Sciences" or the "Company")

### **Director/PDMR Shareholding**

The Company announces that on 21 March 2018 Roger McDowell, a Non-Executive Director of the Company, sold 500,000 ordinary shares of 1 pence each ("Ordinary Shares") at a price of 3 pence per Ordinary Share and bought, into his SIPP, 500,000 Ordinary Shares at a price of 3.006 pence per Ordinary Share (the "Transfer").

Following the Transfer, Mr McDowell's beneficial interest in the Company remains at 2,500,000 Ordinary Shares representing approximately 0.91% of the issued share capital of the Company.

#### For further information:

### **Proteome Sciences plc**

Jeremy Haigh, Chief Executive Officer Ian Pike, Chief Scientific Officer Stefan Fuhrman, Finance Director

Tel: +44 (0)20 7043 2116

### finnCap Limited (Nominated Adviser/Broker)

Geoff Nash/James Thompson Tony Quirke (broking)

Tel: +44 (0)20 7220 0500

# About Proteome Sciences plc. (www.proteomics.com):

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant<sup>®</sup>) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator<sup>™</sup>). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

1.	Details of the person of	lischarging manageria	l responsibilities /	person closel	y associated
----	--------------------------	-----------------------	----------------------	---------------	--------------

a) Name Roger McDowell

2. Reason for the Notification

a) Position/status Non-Executive Directorb) Initial notification/Amendment Initial notification

 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name Proteome Sciences plc b) LEI 213800Q62ICXANKU2986

4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a) Description of the Financial instrument, Ordinary Shares of 1p each

type of instrument

Identification code GB0003104196

b)	Nature of the transaction Price(s) and volume(s)	Purchase and sale of shares 500,000 Ordinary Shares bought at 3.006p per Ordinary Share
		500,000 Ordinary Shares sold at 3.000p per Ordinary Share
d)	Aggregated information:  Aggregated volume  Price	500,000 Ordinary Shares bought at 3.006p per Ordinary Share 500,000 Ordinary Shares sold at 3.000p per Ordinary Share
e) f)	Date of the transaction Place of the transaction	21 March 2018 London Stock Exchange, AIM Market (XLON)